Narjust Florez
MD
Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Aug 19, 2025
Episode
308
Soundcloud
Share
In this episode of Lung Cancer Considered, host Dr. Narjust Florez sits down with Dr. Biagio Ricciuti and Dr. Giannis Mountzios to discuss resistance mechanisms for immune checkpoint inhibitors and more about our understanding of STK11 and KEAP1 co-mutations in conjunction with KRAS mutations as independent predictive factors, as well as emerging therapeutics in this space.
Guest
Giannis Mountzios
MD
Director of the Oncology Department and Clinical Trials Unit
Henry Dunant Hospital Center
Biagio Ricciuti
MD, PhD
Thoracic Medical Oncologist and Data Scientist
Dana-Farber Cancer Institute
Faculty, Harvard Medical School
